MolDX: Combinatorial Pharmacogenomics Limited Coverage Proposed LCD and Billing and Coding: MolDX: Combinatorial Pharmacogenomics Limited Coverage Retirement - Effective August 16, 2020

This proposed Local Coverage Determination (LCD) has been retired under contractor 02101 (AK), 02201 (ID), 02301 (OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY).

Medicare Coverage Database (MCD) Number: DL36325 and DA57413
LCD Title: MolDX: Combinatorial Pharmacogenomics Limited Coverage
LCA Title: Billing and Coding: MolDX: Combinatorial Pharmacogenomics Limited Coverage
Effective Date: August 16, 2020

This proposed policy is being retired because it does not provide additional coverage information beyond what is contained in other existing articles. This is a limited coverage policy for GeneSight®, NeuroIDGenetix, and other combinatorial pharmacogenomics panels in the treatment of psychiatric illness when ordered by a psychiatrist. GeneSight® and NeuroIDGenetix are covered for patients in whom a two gene panel consisting of CYP2C19 and CYP2D6 is reasonable and necessary. The policy MolDX: Pharmacogenomics Testing DL38337 contains complete information. All requirements contained in MolDX: Pharmacogenomics Testing DL38337 must be met.

To access retired proposed LCDs, visit the CMS Medicare Coverage Database Archive.

Visit the Noridian Medicare Coverage Articles webpage to access the Retired articles in the CMS MCD.

 

            Last Updated Wed, 27 May 2020 14:47:16 +0000